Comments on: AstraZeneca withdraws cancer wonder drug

By: Jan

Jan — Mon, 23 Nov 2009 14:40:30 +0000

Development of vandetanib for use in medullary thyroid cancer is not restricted to hereditary MTC. Although patient enrollment in the first phase II study in MTC was restricted to those with hereditary MTC, the current, pivotal study enrolled both hereditary and sporadic MTC.

By: Christine

Christine — Mon, 23 Nov 2009 13:27:56 +0000

Point taken

By: reg myers

reg myers — Mon, 23 Nov 2009 11:04:36 +0000

AZN has not ‘withdrawn’ the drug since it was never given marketing authorization by EMEA or FDA in the first place..
AZN HAS withdrawn it’s regulatory submission of vandetanib for NSCLC. Development of vandetanib in Hereditary Medullary Thyroid cancer is ongoing and in P3 with results expected in early ‘10.
Not really a “wonder drug” either – it has shown inferior PFS/OS to recently rejected Erbitux in NSCLC.